Media stories about Penumbra (NYSE:PEN) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Penumbra earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.778987695529 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
A number of equities research analysts have recently commented on the stock. Canaccord Genuity lifted their price target on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets lifted their price target on shares of Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research upgraded shares of Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. Penumbra currently has an average rating of “Hold” and a consensus target price of $111.50.
Shares of Penumbra (PEN) opened at $88.25 on Thursday. The company has a market cap of $3,000.00 and a PE ratio of 420.24. Penumbra has a twelve month low of $67.95 and a twelve month high of $116.35.
Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. Penumbra had a net margin of 0.28% and a return on equity of 0.25%. The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $79.17 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. The company’s quarterly revenue was up 24.9% compared to the same quarter last year. analysts expect that Penumbra will post -0.15 EPS for the current fiscal year.
In related news, CEO Adam Elsesser sold 24,444 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $105.83, for a total value of $2,586,908.52. Following the sale, the chief executive officer now directly owns 1,231,338 shares of the company’s stock, valued at $130,312,500.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas Wilder sold 345 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $91.15, for a total transaction of $31,446.75. The disclosure for this sale can be found here. Insiders sold 309,026 shares of company stock worth $31,859,942 over the last three months. Corporate insiders own 13.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Penumbra (PEN) Receives Media Sentiment Score of 0.15” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/11/penumbra-pen-receives-media-sentiment-score-of-0-15.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.